Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay082017	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results SAN DIEGO, May 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results 11.9 KB
Toggle SummaryMay102017	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 17.6 KB
Toggle SummaryMay152017	Fate Therapeutics Reports First Quarter 2017 Financial Results ProTmune™ PROTECT Safety Data Expected in Mid-2017 Launched First-in-Human Clinical Trial of FATE-NK100 for Acute Myelogenous Leukemia IND Cleared by FDA for FATE-NK100 with Monoclonal Antibody Therapy in Advanced Solid Tumors Conducted Formal Regulatory Meetings with FDA and MHRA for Engineered Read All »	View HTML Fate Therapeutics Reports First Quarter 2017 Financial Results 34.1 KB
Toggle SummaryAug072017	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2017 Financial Results SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2017 Financial Results 11.9 KB
Toggle SummaryAug082017	Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 Non-Clinical Studies Demonstrate Unique Anti-tumor Activity of Natural Killer Cell Product Candidate FDA Clears IND for FATE-NK100 in Ovarian Cancer SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 18.4 KB
Toggle SummaryAug092017	Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference 11.8 KB
Toggle SummaryAug142017	Fate Therapeutics Reports Second Quarter 2017 Financial Results First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Convenes PROTECT Data Monitoring Committee for ProTmune™ Read All »	View HTML Fate Therapeutics Reports Second Quarter 2017 Financial Results 37.5 KB
Toggle SummaryAug162017	Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy Patent Broadly Protects the Use of Prostaglandins for Enhancing Gene Transfer in Blood Stem Cells Read All »	View HTML Fate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy 15 KB
Toggle SummarySep012017	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be Read All »	View HTML Fate Therapeutics to Present at Upcoming Investor Conferences 15.5 KB
Toggle SummarySep142017	Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A. Read All »	View HTML Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 17 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.